Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02472431
Recruitment Status : Completed
First Posted : June 15, 2015
Last Update Posted : November 30, 2016
Sponsor:
Collaborator:
I.M. Sechenov First Moscow State Medical University
Information provided by (Responsible Party):
Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation

Brief Summary:
Autologous adipose-derived regenerative cells (ADRC) extracted using Celution 800/CRS System (Cytori Therapeutics Inc) from a portion of the fat harvested from the patient's front abdominal wall. ADRC will be administered one-time intracavernosally. This is a single arm study with no control. All patients receive cell therapy.

Condition or disease Intervention/treatment Phase
Erectile Dysfunction Impotence, Vasculogenic Other: Intracavernosal administration of autologous ADRC Procedure: Liposuction Device: ADRC isolation Phase 1 Phase 2

Detailed Description:

Fat tissue obtainment:

Subjects will undergo liposuction under local anesthesia. In this procedure, Ringer's solution with the anesthetic lidocaine and vasoconstrictor adrenaline infused into the adipose compartment to minimize blood loss and contamination of the tissue by peripheral blood cells. 15 minutes later a hollow blunt-tipped 3 mm cannula introduced into the subcutaneous space through small (0.5 cm) incision. The cannula attached to syringe and under gentle suction moved through the adipose compartment, mechanically disrupting the fat tissue. Aspirate volume - approximately 150-200 cc. Procedure time - 30 minutes.

ADRC isolation:

Aspirated fat tissue placed into sterile vessel which inserted into Celution 800/CRS System (Cytori Therapeutics Inc) - closed system for automated and standardized extraction and concentration of ADRC. Celution 800/CRS System drains excess of fluid from fat tissue and estimate it's volume After that lipoaspirate washed extensively with equal volumes of Ringer's solution to remove blood. At the end of this process System indicates required volume of enzyme reagent (Celase®) which should be added immediately by operator. After enzyme treatment Celution 800/CRS System automatically transfers isolated ADRC into washing compartment where ADRC washed and concentrated in 5 mL suspension. Tissue processing time - approximately 60 minutes. ADRC suspension match all requirements listed in technical documentation for Celution 800/CRS System. Obtained ADRC divided into 2 portions. First portion (0.2-0.5 mL) used for counting, viability and sterility assessment. Second portion placed into sterile insulin syringes with needle size 30 G for injection.

Intracavernosal injection of ADRC:

Tourniquet applied immediately prior to injection at the base of the penis. Penis and surrounding skin treated with antiseptic solution. The injection performed on lateral surface of penis bilaterally proximally into the middle and distal parts of corpus cavernosum. Needle is inserted into the corpus cavernosum at the depth of 5-7 mm. Up to 1.0 ml of ADRC suspension injected per single injection. Equal portions of ADRC suspension injected into both corpora cavernosa. Tourniquet removed 20 minutes after ADRC injection.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effectiveness and Safety of Intracavernosal Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction
Study Start Date : April 2015
Actual Primary Completion Date : November 2016
Actual Study Completion Date : November 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ADRC injection Other: Intracavernosal administration of autologous ADRC
Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected intracavernosally.

Procedure: Liposuction
Device: ADRC isolation
ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol




Primary Outcome Measures :
  1. SAEs monitoring [ Time Frame: 2 weeks after treatment ]
    Types, probability and severity of treatment emergent serious adverse events (SAEs)

  2. SARs monitoring [ Time Frame: 2 weeks after treatment ]
    Types, probability and severity of treatment emergent serious adverse reactions (SARs)


Secondary Outcome Measures :
  1. Quality of life monitoring [ Time Frame: Follow up to completion (up to 24 weeks after treatment) ]
    Quality of life estimated by validated questionnaires: the Short Form (36) Health Survey (SF-36), International Index of Erectile Function (IIEF-5), Sexual Encounter Profile (SEP), Erection Hardness Score (EHS), Global Assessment Question (GAQ)

  2. Penile colour Doppler ultrasonography combined with prostaglandin-E1 injection [ Time Frame: Follow up to completion (up to 24 weeks after treatment) ]
    Colour penile Doppler ultrasonography with intracavernosal injection of prostaglandin-E1 10 ug. Arterial diameter, peak systolic flow velocity, end diastolic flow velocity and resistance index measured before and 15 min after prostaglandin-E1 10ug intracavernosal injection.

  3. Endothelial function assessment [ Time Frame: Follow up to completion (up to 24 weeks after treatment) ]
    Endothelial function assessed by EndoPAT or similar device measurements.

  4. Arterial stiffness assessment [ Time Frame: Follow up to completion (up to 24 weeks after treatment) ]
    Arterial stiffness assessed by EndoPAT or similar device measurements.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient suffers from erectile dysfunction
  • IIEF-5 score less than 21
  • Endothelial dysfunction confirmed by EndoPAT measurements
  • Patient is familiar with Participant information sheet
  • Patient signed informed consent form

Non-inclusion Criteria:

  • Contraindications to the local anesthesia or medical history of allergic reactions to local anesthetics
  • Patient prescribed for systemic corticosteroids, immunosuppressive drugs, nonsteroidal antiinflammatory drugs, phosphodiesterase-5 inhibitors
  • Medical history of penile prosthesis implantation
  • Peyronie's disease
  • Subcompensated or decompensated forms of chronic diseases of internal organs
  • Clinically significant abnormalities in results of laboratory tests
  • Any conditions limiting compliance (dementia, neuropsychiatric disease, drug and alcohol abuse etc.)
  • Participation in other clinical trials (or administration of investigational drugs) during 3 months prior inclusion
  • Patients with malignant tumors including postoperative period, patients receiving chemotherapy and/or radiotherapy.
  • Patient's activated partial thromboplastin time exceeds normal levels more than 1,8 times
  • Patients prescribed for anticoagulants treatment or patient received anticoagulants at least one hour prior liposuction
  • Medical history of heterotopic ossifications
  • Patients prescribed for glycoprotein inhibitors treatment
  • Patients with infections or septic condition

Exclusion Criteria:

  • Patient's refusal from the further participation in trial
  • Chronic kidney disease IV- V stages (creatinine clearance < 30 mL/min estimated by Cockcroft-Gault formula)
  • Confirmed syphilis, HIV, hepatitis B or C infections
  • Patients with hypogonadism

Dropout Criteria:

  • Direct indications on immediate initiation of treatment with drugs that have proven effect on erectile function

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02472431


Locations
Layout table for location information
Russian Federation
I.M. Sechenov First Moscow State Medical University
Moscow, Russian Federation, 119991
Federal State Budgetary Institution "Central Clinical Hospital with Outpatient Health Center" of the Business Administration for the President of the Russian Federation; Center for Biomedical Technologies
Moscow, Russian Federation, 121359
Sponsors and Collaborators
Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
I.M. Sechenov First Moscow State Medical University
Investigators
Layout table for investigator information
Principal Investigator: Andrey A Pulin, MD, PhD Federal State Budgetary Institution "Central Clinical Hospital with Outpatient Health Center" of the Business Administration for the President of the Russian Federation
Principal Investigator: Mikhail E Chalyy, MD, PhD, Prof I.M. Sechenov First Moscow State Medical University

Layout table for additonal information
Responsible Party: Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
ClinicalTrials.gov Identifier: NCT02472431     History of Changes
Other Study ID Numbers: RU-CCH-01-01-15
First Posted: June 15, 2015    Key Record Dates
Last Update Posted: November 30, 2016
Last Verified: November 2016

Keywords provided by Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation:
ADRC
Adipose-Derived Regenerative Cells
Fat Tissue
Stem Cells
Erectile Dysfunction
Arteriogenic Impotence
Venogenic Impotence
Vasculogenic Impotence
Male Impotence
Male Sexual Impotence

Additional relevant MeSH terms:
Layout table for MeSH terms
Erectile Dysfunction
Impotence, Vasculogenic
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders